Triplet Regimens for First-Line Advanced Renal Cell Carcinoma

ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, paving the way for future studies.

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Explore the complexities of non-clear cell renal cell carcinoma, its treatment challenges, and promising immunotherapy advancements for better patient outcomes.

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.